Oncovista Innovative Therapies, Inc. (OVIT) is a biopharmaceutical company developing targeted anticancer therapies by utilizing tumor-associated biomarkers. OVIT’s product pipeline is comprised of advanced (Phase II) and early (Phase I) clinical-stage compounds, late preclinical drug candidates and early preclinical leads. The Company’s lead products include Cordycepin (OVI-123) and L-Nucleoside Conjugates (OVI-117). Cordycepin (OVI-123), which contains 3’-deoxyadenosine, is indicated for the treatment of TdT-Positive Refractory Leukemias. L-Nucleoside Conjugates (OVI-117) is a thymidylate synthase (TS) inhibitor. OVI-117 is indicated for the treatment of colon cancer. OVI-117 has shown tumor growth inhibitory activity in human colon, breast and prostate tumors growing in animal models.